Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).


Confirmed Presenting Companies:

 Speaker Profile

Ph.D., Chief Scientific Officer, Covance, Sr VP, LabCorp

Biography
Dr Anderson has been with the LabCorp organization for 26 years and has held a variety of positions including director of operations for ViroMed Laboratories, director of operations for Monogram Biosciences, director of operations for the Center for Molecular Biology and Pathology, director of operations for Integrated Oncology and Genetics, national director of Research and Development, and global head of LabCorp Clinical Trials. Dr Anderson is a member of a variety of professional societies including the American Association for Cancer Research, the American Society of Clinical Oncology and the Association for Molecular Pathology. Dr Anderson’s research interests are in the development and applications for molecular diagnostics, including several examples of companion diagnostics and pharmacogenomics assays. He has authored more than 175 articles and abstracts published in such journals as Genetics, Proceedings of the National Academy of Sciences, Clinical Chemistry, the Journal of Infectious Disease, Human Pathology, American Journal of Obstetrics and Gynecology, Oncogene, the Journal of the National Cancer Institute, Clinical Cancer Research, Breast Cancer Research, BMC Cancer, the Journal of Molecular Diagnostics, Archives of Pathology and Laboratory Investigation and Expert Reviews in Molecular Diagnostics.


 Speaker Profile

Executive Chairman & CEO, Nucleix

Biography
Chris Hibberd has more than 20 years of diagnostics and biopharmaceutical experience in company formation, clinical and business development and commercialization. Prior to taking the helm of Nucleix, he was CEO and co-founder of Astute Medical. He managed a team and secured funding to support a product pipeline that included the launch of NephroCheck®, the first FDA cleared diagnostic for acute kidney injury risk, until its acquisition by bioMérieux. Prior to Astute Medical, he was SVP of corporate development at Biosite, where he managed business development activities that included cofounding Biosite Discovery, a world-class antibody capabilities collaboration, and Biosite’s $1.7 billion acquisition by Inverness Medical. Prior to that, he was a manager at The Boston Consulting Group and a development engineer at Albright & Wilson Americas. He obtained an MBA from the University of Western Ontario and a B.A.Sc. in chemical engineering from the University of Toronto.


Liquid Biopsy Showcase:
Nucleix

Nucleix is revolutionizing cancer treatment by leveraging its highly sensitive PCR and NGS-based EpiCheck® platform to find crucial markers and develop cost-effective screening tests for bladder and lung cancers – helping detect cancer earlier and potentially provide long-term benefit for patients.

EpiCheck®, Cancer Detection At The Earliest Moment
Sensitivity is crucial for early cancer detection. In this talk, Nucleix will outline how it leverages its highly sensitive PCR and NGS-based platforms to find the most important markers and then develop cost-effective PCR-based cancer screening tests for bladder and lung cancers. Highly sensitive tests in cancers like Lung Cancer have the potential to increase screening compliance and drive more patients to treatment when it has the greatest chance of providing long-term benefit.

 Speaker Profile

Ph.D., CEO, Biological Dynamics

Biography
Raj built the company based on technology he developed for his dissertation, where he pioneered the use of AC Electrokinetics for the purpose of blood-based diagnosis. His passion and conviction have led Biological Dynamics through multiple funding rounds, securing $75 million to develop platforms to analyze biomarkers and study feasible applications for early diagnosis of cancer, tuberculosis, and Alzheimer’s disease. Raj founded Biological Dynamics to revolutionize the approach toward the diagnosis and treatment of high burden diseases—the manifestation of his desire to help people with cancer and save lives. Under Raj's vision and guidance, Biological Dynamics has transformed from concept to early-stage startup and is now one of the most innovative diagnostic companies in Southern California, with 47 patents granted (20 in the U.S.) and 44 pending. Raj has published several papers on AC Electrokinetics and was previously named to the Top 30 Under 30 Scientists by Forbes magazine.


Liquid Biopsy Showcase:
Biological Dynamics

Biological Dynamics, Inc. is a healthcare company committed to improving global health outcomes by detecting diseases at their earliest stages. The company's proprietary platform simplifies access to native-state biomarkers and nanoparticles, enabling differentiated multiomics applications.

Exosome Classifier For Early-Stage Cancer Detection
Biological Dynamics is advancing early cancer detection by leveraging its Verita™ platform to capture and analyze exosomes from early-stage (I/II) cancer patient samples. Analysis of exosomal biomarkers enables highly sensitive and specific cancer detection, potentially allowing earlier cancer intervention.

 Speaker Profile

Ph.D., Chief Scientific Officer, Cellular Analytics

Biography
Dr. Kelley’s lab at University of Toronto is focused on building biomolecular sensors and conducting rare/single cell analysis. She has published over 200 scientific papers cited over 18,000 times. Kelly is a recognized expert in translating research discoveries into successful commercial ventures. In 2019, Kelley founded Cellular Analytics, a company that is developing a novel liquid biopsy, which can report on the phenotypic properties of tumors and metastatic disease. Dr. Kelley’s outstanding work has been recognized by a variety of awards, including an ACS Nanoscience Award, the 2016 SLAS Innovation award, an NSERC Brockhouse Award, the 2011 Steacie Prize, an Alfred P. Sloan Research Fellowship, and the Camille Dreyfus Teacher-Scholar award. She has been named one of ‘Canada’s Top 40 under 40’ by The Globe & Mail and a “Top 100 Innovator” by MIT’s Technology Review. Before Cellular Analytics, Kelley founded two biotechnology start ups, GeneOhm Sciences and Xagenic, the former which was successfully acquired by Becton Dickinson in 2005.


Liquid Biopsy Showcase:
Cellular Analytics

Cellular Analytics develops tools that detect and profile surface proteins on rare cells in the blood. Our proprietary microfluidic platform, CytoFind™, has shown high sensitivity and specificity in capturing circulating tumor cells, which are further analyzed to predict patient response to therapy.

Detecting Circulating Tumor Cells Using CytoFind™